[ 1 ] Chang YS, di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood[J]. Proc Natl Acad Sci USA, 2000, 97(26): 14608-14613.
[ 3 ] Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. Aust Med J, 1896, 14: 146-149.
[4]
[ 4 ] Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cance J Clin, 2006, 56(2): 106-130.
[5]
[ 5 ] National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409.
[6]
[ 6 ] Smit AA, Moons-Pasic A. Is lung cancer screening using CT a good idea[J]. Ned Tijdschr Geneeskd, 2011, 155(50): 3960.
[7]
[ 7 ] Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer[J]. Clin Cancer Res, 2009, 15(22): 6980-6986.
[8]
[ 8 ] Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients[J]. J Thorac Oncol, 2009, 4(1): 30-36.
[9]
[ 9 ] Wendel M, Bazhenova L, Boshuizen R, et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology[J]. Phys Biol, 2012, 9(1): 016005.
[10]
Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected[J]. J Clin Oncol, 2011, 29(12): 1508-1511.
[11]
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-742.
[12]
Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials[J]. Clin Lung Cancer, 2012, 13(2): 107-114.
[13]
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non？small-cell lung cancer to gefitinib[J]. N Engl J Med, 2005, 352(8): 786-792.
[14]
Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J]. Proc Natl Acad Sci USA, 2005, 102(21): 7665-7670.
[15]
Engelman JA, Zejnullahu K, Mitsudomi T, et al. Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007, 316(5827): 1039-1043.
[16]
Bean J, Brennan C, Jy S, et al. Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J]. Proc Natl Acad Sci USA, 2007, 104(52): 20932-20937.
[17]
Maheswaran S, Sequist L, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells[J]. N Engl J Med, 2008, 359(4): 366-377.
[18]
Lecharpentier A, Vielh P, Perez-Moreno P, et al. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer[J]. Br J Cancer, 2011, 105(9): 1338-1341.
[19]
Hou M, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer[J]. Am J Pathol, 2011, 178(3): 989-996.
[20]
Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells[J]. PLoS One, 2010, 5(9): 12517.
[21]
Ksikiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells[J]. Pathobiology, 2012, 79(4): 195-208.
[22]
Fisher D, Orazio A. PhaseⅡ andⅢ trials comparison of four chemotherapy regimens in advanced non-small-cell lung cancer (ECOG 1594)[J]. Clin Lung Cancer, 2000, 2(1): 21-22.
[23]
D’Amato TA, Landreneau RJ, McKenna RJ, et al. Prevalence of in vitro extreme chemotherapy resistance in resected non-small-cell lung cancer[J]. Ann Thorac Surg, 2006, 81(2): 440-446.
[24]
Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(12): 1556-1563.
[25]
Ge J, Shi D, Wu C, et al. Fluctuation of circulating tumor cells approach before in patients with lung cancer by real-time fluorescent quantitative-PCR and after radiotherapy[J]. J Cancer Res Ther, 2005, 1(4): 221-226.
[26]
Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phaseⅡ clinical trial of pertuzumab and erlotinib[J]. Clin Cancer Res, 2012, 18(8): 2391-2401.
[27]
Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the cell search Assay and the isolation by size of epithelial tumor cell method[J]. Int J Cancer, 2011, 129(7): 1651-1660.
[28]
Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker[J]. Clin Cancer Res, 2011, 17(4): 827-835.
